 |
160 Products |  |
813 Diseases | | 160 Products |
|
1554 Trials |  |
75234 News |  |
| «12...9899100101102103104105106107108...858859» |
- | carboplatin / Generic mfg., isotretinoin / Generic mfg.
Trial completion date: Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET (clinicaltrials.gov) - Jan 25, 2024
P3, N=379, Active, not recruiting, Sponsor: Children's Oncology Group
Trial completion date: Jan 2024 --> Jan 2025
- Risk of Clostridioides difficile infection in patients with inflammatory bowel disease (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_2005;
For RHEUMA-Bio, the biologics included were infliximab, adalimumab, golimumab, certolizumab, ustekinumab, secukinumab, etanercept, abatacept, tocilizumab, rituximab, guselkumab and ixekizumab...Biologic therapy was not associated with a higher risk of CDI. In IBD patients on biologic therapy, the number of biologics received increased the risk of CDI.
- Traficet-EN (vercirnon) / Amgen, AZD7798 / AstraZeneca
First-time-in-human visualisation of CCR9 expression in the gut by positron emission tomography. (Poster exhibition) - Jan 25, 2024 - Abstract #ECCOIBD2024ECCO_IBD_1276;
P1
Conclusion We have developed a CCR9-specific PET tracer which potentially enables repeatable quantification of CCR9 expression in the gut. Ongoing studies will assess the effects of AZD7798 on CCR9+ cell depletion/repletion in the gut, providing critical data to support the clinical development programme.
- | Tavneos (avacopan) / Kissei, Amgen, Otsuka
Journal: Avacopan for ANCA-associated vasculitis with hypoxic pulmonary haemorrhage. (Pubmed Central) - Jan 25, 2024
We report the use of avacopan as a component of the treatment for pulmonary haemorrhage with hypoxia in AAV. Despite the life-threatening presentations all patients recovered, but attribution of the positive outcomes to avacopan is limited by the concomitant therapies and retrospective observational design.
- | Aranesp (darbepoetin alfa) / Amgen, Kyowa Kirin
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Efficacy and cost-effectiveness of darbepoetin alfa once every 4 weeks versus continuous erythropoietin receptor activator once every 4 weeks for anemia correction in patients with chronic kidney disease not on dialysis. (Pubmed Central) - Jan 25, 2024
Despite the life-threatening presentations all patients recovered, but attribution of the positive outcomes to avacopan is limited by the concomitant therapies and retrospective observational design. The mean cost of DA was approximately one-third that of CERA (34,100
- ||||||| Ostarine (enobosarm) / Veru Inc
Trial suspension, Trial primary completion date, Metastases: ENABLAR-2: Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer (clinicaltrials.gov) - Jan 25, 2024
P3, N=186, Suspended, Sponsor: Veru Inc.
The mean cost of DA was approximately one-third that of CERA (34,100 Active, not recruiting --> Suspended | Trial primary completion date: Sep 2023 --> Jan 2024
- | Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
Enrollment open, HEOR, Metastases: Discontinuation of CDK4/6 Inhibitors in Patients With Metastatic HR Positive, HER2 Negative Breast Cancer (clinicaltrials.gov) - Jan 25, 2024
P2, N=120, Recruiting, Sponsor: Institut f
Active, not recruiting --> Suspended | Trial primary completion date: Sep 2023 --> Jan 2024 Not yet recruiting --> Recruiting
- |||||||| rocatinlimab (KHK4083) / Amgen
New P3 trial, New trial: A Study With Self-administered Rocatinlimab in Adolescent and Adult Participants With Moderate-to-severe AD (clinicaltrials.gov) - Jan 25, 2024
P=N/A, N=0, Withheld, Sponsor: [Redacted]
- | Prolia (denosumab) / Amgen
Enrollment open: Preserving Geriatric Muscle With an Osteoporosis Medication (clinicaltrials.gov) - Jan 24, 2024
P4, N=248, Recruiting, Sponsor: Susan L. Greenspan
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| gresonitamab (AMG 910) / Amgen
Trial termination: Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov) - Jan 24, 2024
P1, N=15, Terminated, Sponsor: Amgen
Not yet recruiting --> Recruiting Completed --> Terminated; Business Decision
- ||| Journal, Adverse events, Real-world evidence, Real-world: Adverse event reporting of four anti-Calcitonin gene-related peptide monoclonal antibodies for migraine prevention: a real-world study based on the FDA adverse event reporting system. (Pubmed Central) - Jan 24, 2024
In addition, there are new AEs that were not listed in the drug instructions but occurred concurrently with multiple drugs, such as Raynaud's phenomenon, weight increase, menstrual disorders, throat tightness, and paraesthesia oral. Common AE signals of the four anti-CGRP mAbs and new AE signals were found to provide a reference for clinical drug selection in clinical practice.
- | Biomarker, Journal, Metastases: The prognostic factors in patients with advanced hepatocellular carcinoma: impact of treatment sequencing. (Pubmed Central) - Jan 24, 2024
Sorafenib followed by regorafenib treatment was associated with a significantly lower risk of mortality rather than upfront sorafenib followed by BSC group or upfront chemotherapy followed by TKIs. These findings underscore the importance of the optimal treatment sequences to improve survival in patients with advanced HCC.
- || Vectibix (panitumumab) / Amgen, Takeda, Lumakras (sotorasib) / Amgen
P1 data, Journal: Sotorasib with panitumumab in chemotherapy-refractory KRAS-mutated colorectal cancer: a phase 1b trial. (Pubmed Central) - Jan 24, 2024
P1/2
Sotorasib-panitumumab demonstrated acceptable safety with promising efficacy in chemotherapy-refractory KRAS-mutated metastatic colorectal cancer. ClinicalTrials.gov identifier: NCT04185883 .
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
Enrollment open, Trial initiation date: Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease (clinicaltrials.gov) - Jan 24, 2024
P1/2, N=100, Recruiting, Sponsor: St. Jude Children's Research Hospital
ClinicalTrials.gov identifier: NCT04185883 . Not yet recruiting --> Recruiting | Initiation date: Nov 2023 --> Feb 2024
- || Ibrance (palbociclib) / Pfizer
Trial primary completion date: EORTC 1745-ETF-BCG: Adjuvant Palbociclib in Elderly Patients With Breast Cancer (clinicaltrials.gov) - Jan 24, 2024
P2, N=366, Active, not recruiting, Sponsor: European Organisation for Research and Treatment of Cancer - EORTC
Not yet recruiting --> Recruiting | Initiation date: Nov 2023 --> Feb 2024 Trial primary completion date: Sep 2027 --> Jun 2026
- | Epidaza (chidamide) / Chipscreen, Nailike (olverembatinib) / Ascentage Pharma, Takeda
New P2 trial: ABC: A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL (clinicaltrials.gov) - Jan 24, 2024
P2, N=67, Recruiting, Sponsor: Nanfang Hospital, Southern Medical University
- || Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder (clinicaltrials.gov) - Jan 23, 2024
P2, N=30, Completed, Sponsor: Indiana University
Trial primary completion date: Sep 2027 --> Jun 2026 Active, not recruiting --> Completed
- | Lumakras (sotorasib) / Amgen, BMS-986466 / BridgeBio, BMS
Journal: Discovery of 1H-pyrazolo[3,4-b]pyrazine derivatives as selective allosteric inhibitor of protein tyrosine phosphatase SHP2 for the treatment of KRAS-mutant non-small cell lung cancer. (Pubmed Central) - Jan 23, 2024
In this study, we used the previously reported SHP2 allosteric inhibitor IACS-13909 as a lead drug for structural derivation and modification, and synthesized three SHP2 inhibitors...Furthermore, the combination therapy of compound 4b and KRAS inhibitor sotorasib would play a strong synergistic effect against NCI-H358 cells...Molecular docking study predicted that compound 4b bound to the allosteric site of SHP2 and formed H-bond interactions with key residues Thr108, Glu110, Arg111, and Phe113. In summary, this study aims to provide new ideas for the development of SHP2 allosteric inhibitors for the treatment of KRAS mutant non-small cell lung cancer.Communicated by Ramaswamy H. Sarma.
- || Review, Journal: Hyperammonemic encephalopathy after tyrosine kinase inhibitors: A literature review and a case example. (Pubmed Central) - Jan 23, 2024
More preclinical evidence is required to unveil the biochemical mechanisms responsible involved in this process and clinical studies are necessary to shed light on the prevalence, risk factors, management and prevention of this adverse event. It is important to monitor neurological symptoms and to measure ammonia levels when manifestations are detected.
- || Krazati (adagrasib) / BMS, Avastin (bevacizumab) / Roche, Lumakras (sotorasib) / Amgen
Review, Journal: KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges. (Pubmed Central) - Jan 23, 2024
Similar to other target therapies, clinical administration of KRASG12C inhibitors (sotorasib and adagrasib) resulted in acquired resistance due to various genetic changes not only in KRAS but in other oncogenes as well. Recent clinical studies are aiming to increase the efficacy of G12C inhibitors by novel combination strategies.
- | ivabradine / Generic mfg.
Journal: PR Interval as a Novel Therapeutic Target of Ivabradine Therapy-Prognostic Impact of Ivabradine-Induced PR Prolongation in Heart Failure Patients. (Pubmed Central) - Jan 23, 2024
This effect may be associated with the dynamics of the trans-mitral flow pattern, in conjunction with heart rate and the PR interval. Clinical implications of PR interval-guided ivabradine therapy remains the future concern.
- | trebananib (AMG 386) / Amgen, Avastin (bevacizumab) / Roche
Journal: Angiopoietin-2 and the Vascular Endothelial Growth Factor Promote Migration and Invasion in Hepatocellular Carcinoma- and Intrahepatic Cholangiocarcinoma-Derived Spheroids. (Pubmed Central) - Jan 23, 2024
Inhibitors targeting ANG-2 (Trebananib) and the VEGF (Bevacizumab) effectively blocked the migration ability of spheroids that had been stimulated with rh-ANG-2 and rh-VEGF. Overall, our findings highlight the critical role played by ANG-2 and the VEGF in enhancing the ability of HCC- and iCCA-derived spheroids to migrate and invade, which are key processes in cancer progression.
- || Review, Journal: Exploring the Spectrum of VEGF Inhibitors' Toxicities from Systemic to Intra-Vitreal Usage in Medical Practice. (Pubmed Central) - Jan 23, 2024
The presentation and mechanisms of adverse effects resulting from VEGFi depend primarily on this distinction and the route of drug administration (systemic or intra-vitreal). This review provides a thorough examination of the causes, recognition, management, and preventive strategies for VEGFi toxicities with the goal of offering support to oncologists in both clinical practice and the design of clinical trials.
- | tarlatamab (AMG 757) / Amgen
Journal: Second-Line Treatment Options for Small-Cell Lung Cancer: A Light at the End of the Tunnel. (Pubmed Central) - Jan 23, 2024
Tarlatamab is a novel promising therapeutic antibody currently under investigation for its potential use in previously treated SCLC patients. This mini-review will explore the current state of second-line treatment options for SCLC, their clinical efficacy, and future directions.
- | dexrazoxane / Generic mfg.
New P3 trial: HO170DLBCL: Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma (clinicaltrials.gov) - Jan 23, 2024
P3, N=324, Not yet recruiting, Sponsor: Stichting Hemato-Oncologie voor Volwassenen Nederland
- | Enrollment change, Trial withdrawal: SMMART Adaptive Clinical Treatment (ACT) Trial (clinicaltrials.gov) - Jan 23, 2024
P1, N=0, Withdrawn, Sponsor: OHSU Knight Cancer Institute
This mini-review will explore the current state of second-line treatment options for SCLC, their clinical efficacy, and future directions. N=25 --> 0 | Not yet recruiting --> Withdrawn
- | volagidemab (REMD-477) / Amgen, REMD Bio
Enrollment closed: Effects of GRA in Patients With Type 1 (clinicaltrials.gov) - Jan 23, 2024
P2, N=30, Active, not recruiting, Sponsor: University of California, San Diego
N=25 --> 0 | Not yet recruiting --> Withdrawn Recruiting --> Active, not recruiting
- | Aimovig (erenumab-aooe) / Amgen, Novartis
Trial completion: CHERUB01: Efficacy of Erenumab in Chronic Cluster Headache (clinicaltrials.gov) - Jan 23, 2024
P2, N=101, Completed, Sponsor: Charite University, Berlin, Germany
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date, Metastases: PalboSarc: Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. (clinicaltrials.gov) - Jan 23, 2024
P2, N=40, Recruiting, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Active, not recruiting --> Completed Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Sep 2024
- | Kepivance (palifermin) / SOBI, Amgen, MB-207 / Fortress
Enrollment open, Enrollment change: Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID) (clinicaltrials.gov) - Jan 23, 2024
P1/2, N=30, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Trial completion date: Dec 2023 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Sep 2024 Suspended --> Recruiting | N=19 --> 30
- Ibrance (palbociclib) / Pfizer
Circulating tumor DNA (ctDNA) monitoring of estrogen receptor- positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) high risk breast cancer during adjuvant endocrine therapy () - Jan 22, 2024 - Abstract #YIR2024YIR_147;
P2
Serial screening increases detection rates as 23% of positive ctDNA tests occurred after an initial negative result. 83% of ctDNA+ patients had true molecular relapse without imaging detectable metastatic disease.
- Ibrance (palbociclib) / Pfizer
Cyclin E cytoplasmatic isoform to predict outcome and benefit to capecitabine treatment in patients with HR+/HER2- metastatic breast cancer from the GEICAM/2013-02 PEARL study. () - Jan 22, 2024 - Abstract #YIR2024YIR_146;
P3
Low molecular weight Cyclin E, detected as Cytoplasmic Cyclin E, identifies luminal MBC that benefit more from CAPE than from PALBO + ET. The low molecular weight Cyclin E isoform appears to be a promising predictive biomarker for the benefit of CAPE and resistance to PALBO + ET treatments in this population.
- Ibrance (palbociclib) / Pfizer
Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer. () - Jan 22, 2024 - Abstract #YIR2024YIR_140;
P3
Required tumor block submission in this phase 3 trial yielded data from unbiased whole-transcriptome RNA sequencing of the primary tumor prior to treatment from 41% of the PALLAS participants. The proportion of luminal A cancers was unexpectedly high (66%), indicating a lower-risk distribution of cancers in this population.
- Ibrance (palbociclib) / Pfizer, Verzenio (abemaciclib) / Eli Lilly
CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer () - Jan 22, 2024 - Abstract #YIR2024YIR_137;
These data support a model whereby ER and RAS signaling converge upon CDK4/6, and CDK4/6 activation is a key survival mechanism when ER signaling is attenuated by treatment in NF1-depleted ER+ breast cancer cells. This apparent addiction for CDK4/6 activity makes NF1-depleted ER+ breast tumors vulnerable to CDK4/6 inhibition, thus creating a potential therapeutic opportunity to match CDK4/6 inhibition with patients who can benefit the most.
- patritumab deruxtecan (U3-1402) / Daiichi Sankyo, Merck (MSD)
A phase 2 study of HER3-DXd in patients (pts) with metastatic breast cancer (MBC). () - Jan 22, 2024 - Abstract #YIR2024YIR_124;
P2
HER3-DXd had an acceptable safety profile, and the data further confirm the clinical activity in MBC in heavy pre-tx MBC across the broad range of HER3 expression levels. Parts B and Z are ongoing and data from this report support the potential entry of HER3-DXd into the therapeutic paradigm in MBC
- Ibrance (palbociclib) / Pfizer, Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab, and Pertuzumab in Hormone Receptor (HR)-Positive, HER2-Positive Metastatic Breast Cancer (ASPIRE) () - Jan 22, 2024 - Abstract #YIR2024YIR_111;
The combination provides a chemotherapy-free alternative for pts with triple positive breast cancers. Further follow up will determine impact on PFS Table 1.
- Ibrance (palbociclib) / Pfizer
Detection of circulating tumor DNA following neoadjuvant chemotherapy and surgery to anticipate early relapse in ER positive and HER2 negative breast cancer: Analysis from the PENELOPE-B trial () - Jan 22, 2024 - Abstract #YIR2024YIR_83;
Clinical imaging and studies of experimental therapy are warranted in this patient population. Testing ctDNA after recent neoadjuvant chemotherapy in luminal-A like breast cancer has relatively low
- Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis, Verzenio (abemaciclib) / Eli Lilly
Primary outcome analysis of the phase 3 SONIA trial (BOOG 2017-03) on selecting the optimal position of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors for patients with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC) () - Jan 22, 2024 - Abstract #YIR2024YIR_36;
Use in first-line prolongs the time on CDK4/6i by 16.56 months and increases toxicity and costs. Second-line use may thus be a preferred option for the majority of patients.
- Ibrance (palbociclib) / Pfizer
PARSIFAL-LONG: Extended follow-up of hormone receptor-positive HER2-negative advanced breast cancer patients treated with fulvestrant and palbociclib vs. letrozole and palbociclib in the PARSIFAL study () - Jan 22, 2024 - Abstract #YIR2024YIR_35;
mPFS and mOS results are consistent with those reported in other first-line trials involving different CDK4/6i. Progression within the first year of first-line CDK4/6i-based regimen for HR+/HER2- ABC pts may be prognostic of less favorable outcomes.
- Kisqali (ribociclib) / Novartis
Randomized Phase II Trial of Endocrine Therapy With or Without Ribociclib After Progression on Cyclin-Dependent Kinase 4/6 Inhibition in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: MAINTAIN Trial () - Jan 22, 2024 - Abstract #YIR2024YIR_27;
Of the 119 randomly assigned participants, 103 (86.5%) previously received palbociclib and 14 participants received ribociclib (11.7%)... In this randomized trial, there was a significant PFS benefit for patients with HR+/HER2- MBC who switched ET and received ribociclib compared with placebo after previous CDK4/6i and different ET.
- Ibrance (palbociclib) / Pfizer
Dynamics and type of ESR1 mutations under aromatase inhibitor or fulvestrant combined with palbociclib after randomization in the PADA-1 trial () - Jan 22, 2024 - Abstract #YIR2024YIR_25;
bESR1mut ctDNA kinetics support the clinical benefit observed in the FUL+PAL arm over the AI+PAL arm. ESR1 mutation type and clonality did not impact the benefit of the treatment
- || Parsabiv (etelcalcetide) / Amgen
Clinical, Review, Journal: Chronic kidney disease associated cardiomyopathy: recent advances and future perspectives. (Pubmed Central) - Jan 22, 2024
The identification of novel biomarkers may lead to future therapeutic targets. Randomized clinical trials in individuals with more advanced CKD would be well posed to expand treatment options for this debilitating condition.
- | Emgality (galcanezumab-gnlm) / Eli Lilly, Daiichi Sankyo, Organon, Ajovy (fremanezumab) / Otsuka, Teva, Aimovig (erenumab-aooe) / Amgen, Novartis
Retrospective data, Journal, Real-world evidence, Real-world: Characteristics associated with response to subcutaneously administered anti-CGRP monoclonal antibody medications in a (Pubmed Central) - Jan 22, 2024
Randomized clinical trials in individuals with more advanced CKD would be well posed to expand treatment options for this debilitating condition. In this real-world setting, anti-CGRP preventives reduced MDM persistently and had similar and large effect sizes on MDM reduction; however, clinical and genetic factors influenced response.
- | Besponsa (inotuzumab ozogamicin) / Pfizer, UCB
Journal: Liver failure after treatment with inotuzumab and polychemotherapy including PEG-asparaginase in a patient with relapsed Philadelphia chromosome-negative acute lymphoblastic leukemia. (Pubmed Central) - Jan 22, 2024
Consolidation with high-dose methotrexate and pegaspargase was administered...The diagnostic criteria for VOD were met, and therapy with defibrotide was initiated...Special caution is required when assessing fitness for further liver toxic regimens. A key takeaway is also the reminder that InO can cause liver damage not only in the form of VOD but also through direct hepatocellular toxicity.
- | Ibrance (palbociclib) / Pfizer, Epidaza (chidamide) / Chipscreen, Verzenio (abemaciclib) / Eli Lilly
Trial completion date, Trial primary completion date, Combination therapy, Metastases: CINDERELLA: Chidamide in Combination With Abemaciclib and Endocrinotherapy?Doctor's Choice? in Breast Cancer Patients Previously Treated With Palbociclib (clinicaltrials.gov) - Jan 22, 2024
P1/2, N=44, Recruiting, Sponsor: Biyun Wang, MD
A key takeaway is also the reminder that InO can cause liver damage not only in the form of VOD but also through direct hepatocellular toxicity. Trial completion date: May 2023 --> May 2025 | Trial primary completion date: Feb 2023 --> Feb 2025
- ||||| zanzalintinib (XL092) / Exelixis
Enrollment change, Metastases: STELLAR-303: Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer (clinicaltrials.gov) - Jan 22, 2024
P3, N=874, Recruiting, Sponsor: Exelixis
Trial completion date: May 2023 --> May 2025 | Trial primary completion date: Feb 2023 --> Feb 2025 N=600 --> 874
- | Blincyto (blinatumomab) / Astellas, Amgen, Nailike (olverembatinib) / Ascentage Pharma
Journal, IO biomarker: Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report. (Pubmed Central) - Jan 22, 2024
This regimen, which has not been reported yet, was safe and effective as the patients achieved minimal residual disease (MRD) negative after 1 cycle of therapy. The management of these cases provides evidence of this new chemo-free regimen as an efficient approach for relapsed or refractory(R/R)Ph+ ALL.
- | Tepezza (teprotumumab) / Roche, Amgen
Journal: Aktuelle Therapieans (Pubmed Central) - Jan 22, 2024
The management of these cases provides evidence of this new chemo-free regimen as an efficient approach for relapsed or refractory(R/R)Ph+ ALL. Teprotumumab (an inhibitory IGF1R antibody) has already been approved in the USA and the therapeutic effects are enormous, especially with regard to the reduction of exophthalmos...No abstract available
- | Ibrance (palbociclib) / Pfizer
Trial completion date, Trial primary completion date: A Study of the Use of Text Message Reminders to Take Palbociclib (clinicaltrials.gov) - Jan 22, 2024
P=N/A, N=45, Active, not recruiting, Sponsor: Memorial Sloan Kettering Cancer Center
Teprotumumab (an inhibitory IGF1R antibody) has already been approved in the USA and the therapeutic effects are enormous, especially with regard to the reduction of exophthalmos...No abstract available Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
- |||||||||| efruxifermin (AKR-001) / Akero Therap
New P3 trial: AK-US-001-0105: A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis (clinicaltrials.gov) - Jan 22, 2024
P3, N=1000, Recruiting, Sponsor: Akero Therapeutics, Inc